Kangyuan Bochuang Biotechnology

Kangyuan Bochuang Biotechnology is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the development of innovative cell therapies for cancer. The company specializes in next-generation CAR-T and TCR-T technologies, with a particular emphasis on overcoming the barriers to treating solid tumors. Their proprietary platforms enable the engineering of immune cells that can better penetrate and survive within the immunosuppressive tumor microenvironment. Beyond its internal therapeutic pipeline, Kangyuan Bochuang operates as a high-end contract research organization (CRO), providing specialized services such as gene editing, stable cell line development, and functional cell-based assays to global pharmaceutical partners. The company's dual-business model combines therapeutic innovation with technical services to drive growth and support the global oncology drug development landscape.